Oncternal Therapeutics | 10-Q: Quarterly report
Oncternal Therapeutics | 8-K: Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
Oncternal Therapeutics | EFFECT: Others
Oncternal Therapeutics | ARS: Annual Report to Security Holders
Oncternal Therapeutics | DEFA14A: Others
Oncternal Therapeutics | DEF 14A: Definitive information statements
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Wills Robert James
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Wills Robert James
Oncternal Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Oncternal Therapeutics | 10-K: Annual report
Oncternal Therapeutics | 8-K: Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director HALE DAVID F
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Wills Robert James
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer BREITMEYER JAMES B
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Leavitt Chase C.
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Krishnan Rajesh
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Yazji Salim
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer VINCENT RICHARD G
Oncternal Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(4.85%)
Oncternal Therapeutics | 8-K: Current report
No Data